Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Events>This Event
  Events - November 2012

Introduction to Sterile Product Manufacture for New Starters and Junior Staff (2 day)

28 Nov 2012 - 29 Nov 2012 - Window Conference Venue, 13 Windsor Street, Islington, London, N1 8QG

Bookmark and Share

Course objectives
To provide training to personnel who are new to the Pharmaceutical or Biotech Industries and have no understanding of cGMP and who intend to work with sterile products, development, manufacturing, registration and facilities.

The course will include:
• A comprehensive background in sterile product manufacturing, regulations and facilities. • Adherence to cGMP and the consequences for non-compliance. • How to initiate development of new formulations, manufacturing, environmental and product monitoring. • Modes of sterilization and types of products.

Who should attend?
The course is ideal for new starters or junior staff working in the Pharmaceutical or Biotech industries who will be exposed to a sterile manufacturing facility or who will be involved in the development of new products. This is an introductory course and the level of detail will be as a broad based overview.
• Clinical Trials Manufacturing Scientists
• Development Scientists
• Regulatory Affairs Personal
• Pharmaceutical Production Personnel
• Quality Control and Quality Assurance Personnel

Course Programme:
Day One (9am – 5pm)
• What is a sterile product?
• Classification of products.
• Why are they sterile?
Basic microbiology. The Regulatory environment.
• cGMP
• Facilities and processing.
• The impact of personnel and materials
• Environmental Monitoring.
• What is the difference and the impact or viable and non-viable contaminants.
Day Two (9am – 5pm)
• Dosage Forms: syringes, ampoules, vials and others
• Sterilisation: Overview of methods of sterilisation, autoclave, dry heat oven, radiation, filtration and EtOH exposure.
• Aseptic vs. Terminally sterilized, how do you decide?
• Areas of specialization. Where do I go from here?

Course Speaker
Paul Cummings
Paul is a Chartered Biologist, a Fellow Member of the Society of Biology and has nearly 30 years experience in the Pharmacy/Pharmaceutical Industry and left GSK in 2009 to pursue a career as an Independent Consultant. His latter roles at GSK were “Head of Sterile Product Clinical Trial Supplies” and “Director of Product Development”, working on new chemical entities from candidate selection through to market launch and product line extensions. He has broad international experience of product transfers, manufacturing and registrations and can provide an invaluable resource to any company.

Discounted rate for registering and paying before 3 October 2012 - 2 day course £1062.00 (+ VAT if applicable, see VAT NOTES)
Full Fee: 2 day course £1180.00 (+ VAT if applicable, see VAT NOTES)
Discount of 10% applies for booking more than 1 delegate. Discount of 10% applies for booking more than 1 course. Maximum discount received is 15%

Further information
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos